2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study

Anna V Tinker; Bhavana Pothuri; Lucy Gilbert; Renaud Sabatier; Jubilee Brown; Sharad Ghamande; Cara Mathews; David M O’Malley; Valentina Boni; Adriano Gravina; Susana Banerjee; Rowan E Miller; Johanna Pikiel; Mansoor R. Mirza; Tao Duan; Sybil Zildjian; Eleftherios Zografos; Jennifer Veneris; Ana Oaknin; study was START Madrid CIOCC

doi:10.1136/ijgc-2022-ESGO.278

Article info

Endometrial cancer

2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study

Free

Authors

Anna V Tinker Department of Medicine, British Columbia Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada PubMed articles Google scholar articles
Bhavana Pothuri Gynecologic Oncology Group (GOG) and Department of Obstetrics/Gynecology, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY PubMed articles Google scholar articles
Lucy Gilbert Division of Gynecologic Oncology, McGill University Health Centre, Montreal, QC, Canada PubMed articles Google scholar articles
Renaud Sabatier Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille University, Marseille, France PubMed articles Google scholar articles
Jubilee Brown Division of Gynecologic Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC PubMed articles Google scholar articles
Sharad Ghamande Department of Obstetrics & Gynecology, Georgia Cancer Center, Augusta University, Augusta, GA PubMed articles Google scholar articles
Cara Mathews Women and Infants Hospital of Rhode Island, Providence, RI PubMed articles Google scholar articles
David M O’Malley Division of Gynecologic Oncology and Gynecologic Oncology Phase I Program, The Ohio State University and the James Cancer Center, Columbus, OH PubMed articles Google scholar articles
Valentina Boni NEXT Oncology Hospital Universitario Quirónsalud Madrid, Madrid, Spain PubMed articles Google scholar articles
Adriano Gravina Clinical Trial Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy PubMed articles Google scholar articles
Susana Banerjee Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom PubMed articles Google scholar articles
Rowan E Miller University College London, St. Bartholomew’s Hospitals London, London, United Kingdom PubMed articles Google scholar articles
Johanna Pikiel Department of Chemotherapy, Regional Center of Oncology, Gdansk, Poland PubMed articles Google scholar articles
Mansoor R. Mirza Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark, Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, Denmark PubMed articles Google scholar articles
Tao Duan GSK, Pennington, NJ PubMed articles Google scholar articles
Sybil Zildjian GSK, Waltham, MA*Current affiliation; affiliation at the time of s, ed. †Employed by GSK at the time the study was conduct PubMed articles Google scholar articles
Eleftherios Zografos GSK, London, United Kingdom PubMed articles Google scholar articles
Jennifer Veneris GSK, Waltham, MA PubMed articles Google scholar articles
Ana Oaknin Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articles Google scholar articles
study was START Madrid CIOCC
Google scholar articles

Citation

Tinker AV, Pothuri B, Gilbert L, et al

2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study

International Journal of Gynecologic Cancer 2022;32:A130.

Publication history

First published October 20, 2022.

Online issue publication

October 27, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password